Phagocytosis in vitro of polyethylene glycol-modified liposome-encapsulated hemoglobin by human peripheral blood monocytes plus macrophages through scavenger receptors

Life Sciences

Volumn 70, Issue 3, 2001, Pages 291-300

  Shibuya Fujiwara, Nobuko ^a   Hirayama, Fumiya ^a,c   Ogata, Yoshitaka ^b   Ikeda, Hisami ^a   Ikebuchi, Kenji ^a  

^a JAPANESE RED CROSS SOCIETY   (Japan)

^b TERUMO CORPORATION   (Japan)

^c SUWA RED CROSS HOSPITAL   (Japan)

Author keywords

CD14; CD36; CD51 61; Liposome encapsulated hemoglobin (LEH); Phagocytosis; Polyethylene glycol (PEG)

Indexed keywords

HEMOGLOBIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1; MACROGOL; MONOCLONAL ANTIBODY; SCAVENGER RECEPTOR; VITRONECTIN RECEPTOR;

ARTICLE; BLOOD; CIRCULATION; CONTROLLED STUDY; DRUG EFFECT; ERYTHROCYTE; FLUORESCENCE; HALF LIFE TIME; HUMAN; HUMAN CELL; MACROPHAGE; MONOCYTE; NORMAL HUMAN; OPSONIZATION; PHAGOCYTOSIS;

ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, CD36; FLOW CYTOMETRY; HEMOGLOBINS; HUMANS; INTEGRIN ALPHAV; INTEGRIN BETA3; LIPOSOMES; MACROPHAGES; MEMBRANE PROTEINS; MONOCYTES; PHAGOCYTOSIS; PLATELET MEMBRANE GLYCOPROTEINS; POLYETHYLENE GLYCOLS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, LIPOPROTEIN; RECEPTORS, SCAVENGER; SCAVENGER RECEPTORS, CLASS B;

EID: 0035824729     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(01)01392-3     Document Type: Article

References (39)

1. Hemoglobin-based red cell substitutes: Unsolved issues and further directions
2. Modified hemoglobin-based blood substitutes: Crosslinked, recombinant and encapsulated hemoglobin
3. Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution
4. The action of diaspirin cross-linked haemoglobin blood substitute on human arterial bypass conduits
5. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery
6. Safety and efficacy of encapsulated hemoglobin in hemorrhagic shock
7. Recognition and clearance of liposomes containing phosphatidylserine are mediated by serum opsonin
8. Complement dependent and independent liposome uptake by peritoneal macrophages: Cholesterol content dependency
9. Complement activation in vitro by the red cell substitute, liposome-encapsulated hemoglobin: Mechanism of activation and inhibition by soluble complement receptor type 1
10. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: A model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody
11. Complement-mediated acute effects of liposome-encapsulated hemoglobin
12. Surface-modified liposomes: Assessment and characterization for increased stability and prolonged blood circulation
13. (1991) Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo
14. Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids
15. Poly(ethylene glycol)-conjugation and deoxygenation enable long-term preservation of hemoglobin-vesicles as oxygen carriers in a liquid state
16. Polyethylene glycol-modified liposome-encapsulated hemoglobin: A long circulating red cell substitute
17. Characteristics of Neo Red Cell, their function and safety: In vivo studies
18. Effect of sterical stabilization on macrophage uptake in vitro and on thickness of the fixed aqueous layer of liposomes made from alkylphosphocholines
19. Surface modification of liposomes with polyethylene glycol prevents liposome aggregation in blood plasma
20. Liposomes for the sustained drug release in vivo
21. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
22. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: Studies with poly(ethylene glycol)-coated vesicles
23. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo
24. Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes
25. Human CD14 mediates recognition and phagocytosis of apoptotic cells
26. CD36 is required for phagocytosis of apoptotic cells by human macrophages that use either a phosphatidylserine receptor or the vitronectin receptor (avb3)
27. Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis
28. Human glomerular mesangial cell phagocytosis of apoptotic neutrophiles. Mediated by a novel CD36-independent vitronectin receptor/trombospondin recognition mechanism that is uncoupled from chemokine secretion
29. Molecules from Staphylococcus aureus that bind CD14 and stimulate innate immune responses
30. Mechanisms of stimulation of interleukin-1 beta and tumor necrosis factor-alpha by Mycobacterium tuberculosis components
31. CD14 is a pattern recognition receptor
32. Lipopolysaccharide binding protein and soluble CD14 catalyze exchange of phospholipids
33. Structures and functions of multiligand lipoprotein receptors: Macrophage scavenger receptors and LDL receptor-related protein (LRP)
34. Binding of sulfosuccinimidyl fatty acids to adipocytes membrane proteins: Isolation and amino-terminal sequence of 88-kDa protein implicated in transport of long-chain fatty acids
35. CD36 is a receptor for oxidized low density lipoprotein
36. Phosphatidylserine receptors: Role of CD36 in binding of anionic phospholipid vesicles to monocytic cells
37. The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids
38. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis
39. Immunosuppressive effects of apoptotic cells